Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women

Hum Reprod. 1999 May;14(5):1217-8. doi: 10.1093/humrep/14.5.1217.

Abstract

It is now recognized that female carriers of fragile X premutations are at increased risk of premature ovarian failure. We have studied 51 premenopausal women from fragile X families, to determine whether premutation carriers have variations in the hormonal markers of menopause, compared to full mutations and controls. We found a significant increase in serum follicle stimulating hormone in premutation carriers, suggesting that as a group they will enter menopause before full mutation carriers and unaffected controls. These results have important implications for fertility in these women.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Female
  • Follicle Stimulating Hormone / blood*
  • Fragile X Syndrome / blood
  • Fragile X Syndrome / diagnosis*
  • Genetic Carrier Screening
  • Humans
  • Middle Aged
  • Mutation
  • Predictive Value of Tests
  • Premenopause / blood
  • Primary Ovarian Insufficiency / blood
  • Primary Ovarian Insufficiency / diagnosis*
  • Primary Ovarian Insufficiency / genetics

Substances

  • Follicle Stimulating Hormone